Last reviewed · How we verify
Pegasys plus Entecavir
Pegasys plus Entecavir is a Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved.
Pegasys (Peginterferon alfa-2a) is used in combination with Entecavir for the treatment of Chronic Hepatitis B. Entecavir is a small molecule antiviral medication, also known as ANHYDROUS ENTECAVIR, used to treat various conditions including Chronic Hepatitis B.
At a glance
| Generic name | Pegasys plus Entecavir |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (PHASE2)
- Impact of Fatty Liver on Hepatitis B Therapy
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
- To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (NA)
- A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegasys plus Entecavir CI brief — competitive landscape report
- Pegasys plus Entecavir updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Pegasys plus Entecavir
What is Pegasys plus Entecavir?
Who makes Pegasys plus Entecavir?
What development phase is Pegasys plus Entecavir in?
Related
- Manufacturer: National Taiwan University Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing